This article was originally published in The Gray Sheet
Automated bench-top detection system can determine the presence of chlamydia and gonorrhea in up to 5 mL of urine in under 30 minutes, as opposed to the five hours to two days required by current testing methods, the Sunnyvale, California-based firm says May 28. After selecting a strategic partner, the company will seek regulatory approval to develop and market the device. The system also is being evaluated for detection of anthrax and other biological organisms from nasal swabs or other media
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.